NanoVibronix Inc Cash Flow Conversion Efficiency
NanoVibronix Inc cash flow conversion efficiency. Based on the latest financial reports, NanoVibronix Inc (NAOV) has a cash flow conversion efficiency ratio of -0.046x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.97 Million) by net assets ($42.46 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of NanoVibronix Inc (2011–2024)
Cash flow conversion efficiency of NanoVibronix Inc from 2011 to 2024. This chart illustrates how NanoVibronix Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View NanoVibronix Inc stock quote for real-time trading data and today's change.
NanoVibronix Inc Cash Flow Conversion Ratio Explained
NanoVibronix Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
NanoVibronix Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of NanoVibronix Inc ranked by their cash flow conversion efficiency. Also see NanoVibronix Inc stock valuation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Innity Corporation Bhd
KLSE:0147
|
-0.154x |
|
Sawang Export Public Company Limited
BK:SAWANG
|
0.001x |
|
Acurx Pharmaceuticals LLC
NASDAQ:ACXP
|
-0.210x |
|
Newton Golf Company
NASDAQ:NWTG
|
0.492x |
|
Pure Biologics Spólka Akcyjna
WAR:PUR
|
0.011x |
|
CPPGroup Plc
F:4CV1
|
-2.851x |
|
AHT Syngas Technology NV
F:3SQ1
|
0.008x |
|
Neola Medical AB
ST:NEOLA
|
-0.025x |
Annual Cash Flow Conversion Efficiency for NanoVibronix Inc (2011–2024)
The table below shows the annual cash flow conversion efficiency of NanoVibronix Inc from 2011 to 2024. Review NanoVibronix Inc free cash flow efficiency to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $627.00K | $-2.52 Million | -4.013x | -344.28% |
| 2023-12-31 | $3.99 Million | $-3.60 Million | -0.903x | +58.49% |
| 2022-12-31 | $3.23 Million | $-7.04 Million | -2.176x | -214.57% |
| 2021-12-31 | $6.31 Million | $-4.37 Million | -0.692x | +51.16% |
| 2020-12-31 | $2.39 Million | $-3.39 Million | -1.416x | +50.71% |
| 2019-12-31 | $1.35 Million | $-3.87 Million | -2.874x | +62.52% |
| 2018-12-31 | $463.00K | $-3.55 Million | -7.667x | -1176.96% |
| 2017-12-31 | $3.63 Million | $-2.18 Million | -0.600x | -197.88% |
| 2016-12-31 | $-2.50 Million | $-1.53 Million | 0.613x | -91.34% |
| 2015-12-31 | $-209.00K | $-1.48 Million | 7.081x | +4318.76% |
| 2014-12-31 | $-5.62 Million | $-900.00K | 0.160x | -12.23% |
| 2013-12-31 | $-3.30 Million | $-602.00K | 0.183x | -57.50% |
| 2012-12-31 | $-1.83 Million | $-787.00K | 0.430x | -54.06% |
| 2011-12-31 | $-585.00K | $-547.00K | 0.935x | -- |
About NanoVibronix Inc
NanoVibronix, Inc., through its subsidiaries, focuses on non-invasive biological response-activating devices that target biofilm prevention, pain therapy, wound healing, and at home administration without medical professional assistance. Its product portfolio includes UroShield, an ultrasound-based product that is designed to prevent bacterial colonization and biofilm in urinary catheters, increa… Read more